1080 results about "Growth factor" patented technology

The invention relates to the technical field of medical dressings, in particular to a perianal drug dressing of a multi-layer flow guide composite fabric and a preparation method and application of the perianal drug dressing of the multi-layer flow guide composite fabric. The perianal drug dressing is of a four-layer structure, a wet tissue adhesion layer is made of polydopamine modified chitosan / oxidized hyaluronic acid hydrogel, and wet-state adhesion is achieved; the drug sustained-release layer is used for dispersing mesoporous silica loaded with ciprofloxacin hydrochloride / defensin and chitosan microspheres loaded with epidermal growth factors / lonicera japonica into a polycaprolactone fiber membrane to achieve synergistic antibacterial and healing promotion; the directional flow guide layer is of a gradient wettability sandwich structure with a bionic micro-channel, and one-way rapid drainage can be achieved; the high-absorption outer layer is carboxymethyl cellulose / sodium polyacrylate composite sponge, liquid is locked efficiently, the wound surface is kept dry and comfortable, the clinical problem in perianal infection wound treatment can be effectively solved, and the treatment effect and the patient comfort are remarkably improved.

The invention relates to the technical field of biomedicine, in particular to stem cell exosome-loaded bi-crosslinked hydrogel as well as preparation and application thereof, and the bi-crosslinked hydrogel comprises the following components in parts by weight: 50-90 parts of a matrix polymer; 0.1 to 5 parts of an active load; 1 to 10 parts of cyclodextrin; 5 to 20 parts of modified chitosan; 0.01 to 1 part of a photoinitiator; and 0.01 to 0.5 part of growth factors. Through double-network design of physical / chemical primary cross-linking and photo-initiation secondary cross-linking, the bottleneck that the mechanical property and the machinability of the traditional single cross-linking hydrogel are difficult to consider at the same time is overcome; meanwhile, the human umbilical vein endothelial cell exosome is introduced, and efficient loading, uniform dispersion and degradation coupling slow release of the exosome are realized by virtue of beta-cyclodextrin inclusion and a double-crosslinking network. Therefore, the problems of mechanics, degradation, cross-linking speed or tissue adhesion of cross-linked hydrogel in the prior art are solved.

The invention relates to the technical field of repair materials, and particularly discloses an extracellular matrix fiber material as well as a preparation method and application thereof. The invention discloses a preparation method of an extracellular matrix fiber material. The preparation method comprises the following steps: taking animal tissues, and carrying out virus inactivation, decellularization and antigen removal, degreasing, drying, grinding and sterilization; the decellularization and antigen removal method comprises the following specific steps: sequentially soaking a sample with a surfactant solution for h; then, soaking treatment is carried out by adopting a salt-alkali solution which contains 0.05-3 mol / L of salt and has the pH value of 8-11; then carrying out soaking treatment by adopting a 0.1-1wt% enzyme solution; and in degreasing, one or more of normal hexane, trichloromethane, dichloromethane, methanol, ethanol, acetone, diethyl ether and ethyl acetate are used for soaking the sample. According to the technical scheme, the ECM powder particle material with high growth factor content is prepared.

The invention discloses composite hydrogel bio-ink with a function of space-time delivery of double growth factors as well as a preparation method and application of the composite hydrogel bio-ink, and belongs to the technical field of biomedical materials and tissue engineering. According to the preparation method, imidazolyl-modified methacrylated gelatin and double-bonded PF127 are compounded, and meanwhile, free vascular endothelial growth factors and connective tissue growth factor-loaded PLGA microspheres are entrapped in a system, so that the bio-ink with excellent printability, high adhesion, swelling resistance and space-time delivery function is formed; the bio-ink physically has the advantages of high printing fidelity, low swelling property, high mechanical strength and strong tissue adhesion of a synthetic material; in biology, the system can be used as an intelligent carrier to realize programmed space-time delivery of various growth factors, so that complex cell biological behaviors are accurately arranged, and real regeneration of functional tissues is guided.

The invention belongs to the field of biological medicines, and finds and verifies that taquinimod or pharmaceutically acceptable salts thereof can be used for preparing medicines for treating endometriosis for the first time, and is particularly suitable for progestogen-resistant, recurrent or deep infiltration type endometriosis. The action mechanism of the taquinimod is as follows: the taquinimod can down-regulate the expression of S100A9 protein and reduce the infiltration of S100A9 + macrophages by inhibiting an NF-kappa B signal channel so as to further inhibit the expression of a vascular endothelial growth factor receptor 1 (VEGFR1) and a matrix metalloproteinase 2 (MMP2), finally block pathological angiogenesis and inhibit the growth of ectopic lesions. Animal experiments show that the taquinimod can significantly reduce the number and weight of nidus of a mouse model with endometriosis. The invention provides a brand-new non-hormone treatment choice with a clear action mechanism for clinical application, provides a pharmaceutical composition containing a specific dosage and a drug combination scheme, and has an important clinical value.

The invention discloses a muscle-bone regeneration sustained-release preparation for targeting knee joint cartilage and a preparation process thereof, the preparation is composed of a cartilage targeting peptide modified PLGA-hyaluronic acid composite nanoparticle sustained-release carrier, an active regeneration component, a biocompatible matrix and an anti-inflammatory component, nanoparticles are prepared by a multiple emulsion solvent evaporation method, and targeting peptide is modified; the composite concentrated growth factors, stem cells and traditional Chinese medicine extracts have the functions of targeted enrichment, long-acting slow release, anti-inflammation and cartilage regeneration promotion, and can be used for knee joint cartilage defect repair.

The invention relates to the technical field of rhinitis spray preparation, in particular to a method for preparing allergic rhinitis spray from umbilical cord mesenchymal stem cell exosomes, which comprises the following steps: 1, umbilical cord treatment; 2, culturing umbilical cord mesenchymal stem cells; 3, preparing an umbilical cord mesenchymal stem cell exosome; and 4, preparing the rhinitis spray. The rhinitis spray prepared by the method disclosed by the invention is simpler and more convenient to use. The exosome, the platelet growth factor and other substances in the rhinitis spray well solve the core problems of single curative effect, large side effect, low compliance and the like in the traditional rhinitis treatment, and through the induction and repair functions of the stem cell exosome and the bactericidal ability of the antibacterial peptide, the nasal cavity environment is improved, the anaphylactic reaction is reduced, the nasal mucosa is repaired, and the rhinitis treatment effect is improved. The allergic rhinitis is expected to be fundamentally treated.

The invention discloses a pseudo-ginseng exosome-like nano vesicle loaded with an epidermal growth factor / application of the pseudo-ginseng exosome-like nano vesicle in wound healing. The research shows that not all exosome-like nano-vesicles from Chinese herbal medicines capable of promoting wound healing have the effect of promoting wound healing, the action mechanism of the pseudo-ginseng exosome-like nano-vesicles in wound healing is further explored, and the research shows that PNVs can promote the proliferation and migration of an epidermal keratinocyte line, so that the PNVs can be used for promoting the healing of the wound. The treatment can be realized by regulating and controlling the activity of immune cells to promote cell proliferation and migration, and the wound healing effect of the EGF-loaded EGF-coated PNVs is remarkably enhanced, so that the EGF-loaded EGF-coated PNVs have a synergistic effect. The invention not only provides a theoretical basis for deeply researching PELNVs, but also provides a new method and a new idea for treating acute wounds.

The invention discloses a platelet growth factor derived polypeptide as well as a composition and application thereof. The amino acid sequence of the polypeptide is shown as Seq ID No: 1 (RP1601: LLKLLKKLLKKLLKK). KKIIKKL is used as a core active sequence, a variant library is designed by adopting a special design rule (AABB cycle rule), optimization is carried out by combining a polypeptide activity prediction system with a molecular docking technology, finally five candidate polypeptides are screened out, the polypeptide RP1601 has a better balance expression between drug effect and safety, and the polypeptide RP1601 is simple in structure, easy to synthesize and optimize and high in stability, and can be used for preparing a polypeptide RP1601. Therefore, the polypeptide is determined as an optimal candidate polypeptide; based on excellent anti-inflammatory, repair-promoting and anti-oxidation characteristics of the polypeptide, the invention further provides application of the polypeptide in cosmetics and medicines.

The invention provides vitamin B12 modified microspheres capable of efficiently loading His tag recombinant protein as well as a preparation method and application of the vitamin B12 modified microspheres, and belongs to the technical field of biological medicines. The preparation method of the vitamin B12 modified microsphere for efficiently loading the His tag recombinant protein comprises the following steps: (1) carrying out esterification reaction on unsaturated fatty acid containing sulfydryl, disulfide bond or olefinic bond, saturated fatty acid and vitamin B12 to prepare an amphiphilic vitamin B12-lipid conjugate; and (2) taking the amphiphilic vitamin B12-lipid conjugate, PLGA (poly (lactic-co-glycolic acid)), a multi-sulfydryl cross-linking agent and a photoinitiator as raw materials, and preparing the raw materials into microspheres by adopting a microfluidic method, so as to obtain the vitamin B12 modified microspheres capable of efficiently loading various His tag recombinant proteins. The microsphere provided by the invention overcomes the problems of protein load stability and burst release of traditional microspheres, and various different His tag recombinant growth factors can be flexibly selected according to the requirements on different growth factors in treatment of complex bone defects caused by different pathogenesis.

A microfluidic 3D-printed hydrogel based on fish liver decellularized extracellular matrix for liver regeneration and a preparation method. The hydrogel is prepared by means of combining fish liver decellularized extracellular matrix (dECM) and gelatin methacryloyl (GelMA), and loading induced pluripotent stem cell-derived hepatocytes (iPSC-heps) for liver regeneration. The microfluidic 3D-printed hydrogel based on fish liver decellularized extracellular matrix exhibits excellent biocompatibility, retains intact endogenous growth factors, maintains the biological activity of cells, ensures the effective encapsulation of the cells, and facilitates the robust functional expression of the iPSC-heps. After in-vivo transplantation, the survival rate and liver function of mice with acute liver failure are significantly improved, and liver regeneration and repair are promoted.

According to various aspects of this disclosure, the present disclosure relates to methods for reducing kidney inflammation, reducing kidney fibrosis, reducing oxidative stress in the kidney, preventing or reducing the likelihood of chronic kidney disease (CKD), treating or preventing acute kidney injury (AKI) or treating a kidney disease in a subject in need thereof comprising administering, e.g., intramuscularly, to the subject a recombinant adeno-associated virus (rAAV) vector, wherein the rAAV vector comprises a vector genome comprising a nucleotide sequence encoding a Fibroblast growth factor 21 (FGF21) or a functional fragment thereof and an AAV capsid (e.g., AAV1 serotype), optionally, wherein the subject does not suffer from diabetes.

The invention relates to the technical field of cell biology, in particular to a culture medium for inducing neural stem cells and application thereof.The culture medium for inducing the neural stem cells comprises a neural ectoderm induction culture medium and a neural stem cell induction culture medium; the neural ectoderm induction culture medium is prepared from a basic culture medium, an N-2 additive, a B-27 additive, an inhibitor SB431542 and an inhibitor Dorsomorphin, the neural stem cell induction culture medium is prepared from a basic culture medium, an N-2 additive and a B-27 additive, the basic culture medium is composed of a DMEM / F12 culture medium, a Neurobase culture medium, GlutaMax and non-essential amino acid NEAA. The problems that neural stem cells obtained through an existing single-layer adherent induction method based on small molecules or growth factors are uneven in differentiation and low in purity are solved.

The invention relates to the technical field of functional drinks, in particular to a polypeptide synergistically strengthened cubilose collagen composite drink with a breast enlarging function and a preparation method of the polypeptide synergistically strengthened cubilose collagen composite drink. The drink contains fish collagen tripeptide, elastin peptide, cubilose peptide, pueraria mirifica isoflavone, red clover isoflavone and saffron crocus extract. A lipidosome delivery system is adopted to entrap polypeptide to form a nano-scale compound, nano-emulsion entraps phytoestrogen, and berry polyphenol and lipidosome-polypeptide form a stable ternary compound. Through the multi-way synergistic effect that phytoestrogen activates a mammary gland estrogen receptor, polypeptide promotes connective tissue collagen synthesis and cubilose peptide activates a growth factor signal, mammary gland development is remarkably promoted, the breast enlarging effect is achieved, the bioavailability reaches 85% or above, and the retention rate of active ingredients stored at normal temperature for 24 months is larger than 90%.

The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.

The invention discloses a culture medium for adipose-derived stem cells, and particularly relates to the technical field of stem cell culture. The culture medium comprises a basic culture medium and nerve-vascular niche components, wherein the basic culture medium comprises DMEM / F12, 10% of human-derived platelet lysate and 1% of antibiotic solution; the nerve-vascular niche comprises the following components: a Slit3 recombinant protein, a nerve growth factor-beta, a glial cell-derived neurotrophic factor, a lysyl oxidase inhibitor, dexamethasone, 3-isobutyl-1-methylxanthine and insulin. The traditional fetal calf serum is replaced by the human-derived platelet lysate, so that the risks of immunological rejection and pathogen pollution are avoided; through the synergistic effect of nerve-vessel niche factors, blood vessel maturation and innervation are promoted, programmed mechanical stretching culture is combined, the adipogenic differentiation efficiency of adipose-derived stem cells is remarkably improved, and engineered adipose tissue which is huge in lipid droplet, compact in structure and provided with a nerve-vessel network is formed.

The disclosure relates to GRAIL-1 peptide products and methods to target mutant p53 for treating p53-mutant related disease conditions such as Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC). The disclosure also relates to methods to monitor the therapeutic response of treated BE and EAC patients by detecting expression of epidermal growth factor receptor (EGER) on BE and EAC cells.

The present disclosure provides a construct comprising a coding sequence operably linked to a promoter, wherein the coding sequence encodes a vascular endothelial growth factor (VEGF) binding agent or a portion thereof. In some embodiments, a construct is an AAV construct. In some embodiments, an AAV construct is a part of an AAV particle. Compositions comprising constructs and AAV particles described herein can be useful in treating hearing loss, for example, hearing loss associated with vestibular schwannoma.

The present invention relates to a method for assessing whether a subject has Polycystic Ovarian Syndrome (PCOS) or is at risk of developing PCOS, to a method of selecting a patient for therapy of PCOS, to a method for monitoring PCOS progression or for monitoring response to treatment and to a computer-implemented method for assessing a subject with suspected PCOS, by determining the amount or concentration of Fibroblast Growth Factor-Binding Protein 1 (FGFBP1) in a sample of the subject.

The invention discloses construction of a Guangdong small-ear spotted pig spermatogonial stem cell in-vitro culture system and screening of surface markers, and belongs to the technical field of cell culture.The technical scheme includes that testis are broken firstly, then enzyme digestion, density gradient centrifugal purification and differential adherent purification are conducted, and purified spermatogonial stem cells are obtained; inoculating the obtained spermatogonial stem cells to feeder layer cells and culturing in a culture medium; the culture medium is a DMEM culture medium added with FBS and growth factors; the mass fraction of the FBS in the DMEM culture medium is 8-12%, an enzyme digestion method, a density gradient centrifugation method and a differential adhesion method are combined for application, the Guangdong small-ear spotted pig spermatogonia stem cells with certain purity are obtained, cells enriched and purified in vitro can proliferate massively, and an in-vitro culture system of the Guangdong small-ear spotted pig spermatogonia stem cells is established.

An osteogenic composition comprises growth-factor augmented cortical bone and cancellous bone having viable endogenous osteogenic cells that remain adherent to the cancellous bone. The growth-factor augmented cortical bone comprises demineralized cortical bone amplified with growth factors derived from a demineralized bone, and the cancellous bone not having been subjected to a loosening agent. The osteogenic composition is cryopreserved or lyopreserved. A method for preparing an enhanced graft composition with improved osteoinductive properties includes processing demineralized cortical bone; solubilizing growth factors from demineralized bone; and mixing the demineralized cortical bone with the solubilized growth factors.

The present application relates to a nutritional composition, a product comprising the same and use thereof in the preparation of a product for alleviating synaptic plasticity impairment of a body. The nutritional composition comprises: docosahexaenoic acid (DHA) and / or a metabolic precursor thereof, sodium hyaluronate (SH), and lactoferrin (LF). When docosahexaenoic acid (DHA), sodium hyaluronate (SH) and lactoferrin (LF) are used in combination, they can synergistically alleviate synaptic plasticity impairment of a body, in particular, increase nerve growth factor (NGF) content and / or brain-derived neurotrophic factor (BDNF) content in PC12 cells of the body, and / or increase expression of synaptic-related proteins in PC12 cells of the body.

The present invention relates to compositions targeting epidermal growth factor receptors and methods of making and using the same, and particularly provides antibody binding domains for the differentiation cluster 3 T cell receptor (CD3), antibody binding domains for the epidermal growth factor receptor (EGFR), cleavable linker sequences, and protease activatable bispecific fusion proteins, a T cell adaptor, such as a protease, can be activated, as well as uses and methods of treatment.

The invention belongs to the cross technical field of veterinary medicine and biomedicine, and relates to a construction and evaluation method of a dog spontaneous breast cancer organoid model, which specifically comprises the following steps: (1) obtaining dog spontaneous breast cancer tissues through operation or biopsy, separating tumor tissues under sterile conditions, and carrying out fine enzymolysis digestion treatment to obtain dog spontaneous breast cancer tissues; obtaining a single-cell suspension; and (2) inoculating the single-cell suspension into a three-dimensional culture system, carrying out three-dimensional culture by adopting a culture medium containing EGF, FGF and B27 in combination with a growth factor, promoting the growth and amplification of the breast cancer organs, and carrying out timely passage according to the growth condition so as to maintain the activity of the model. The model constructed by the invention completely retains genetic heterogeneity and pathological microenvironment of primary tumors, does not need gene editing, is simple and convenient to operate and low in cost, is particularly suitable for individual drug sensitivity detection of pet dogs, and provides an efficient and high-simulation experimental platform for dog breast cancer mechanism research and clinical precise medication.

Particulated and reconstituted tissues comprising small, densely packed tissue microparticles encapsulated in a tissue specific promoting gel packed at a percolation threshold that can be transplanted into damaged tissue thereby facilitating regeneration following trauma to the tissue. The engineered microparticle construct for tissue replacement and repair, as taught herein, provides numerous benefits including (1) encouraging a regenerative response in damaged tissue regions, (2) mimicking the structural support of native tissue, (3) establishing an environment that promotes attachment, migration, and differentiation of infiltrating stem cells, and (4) providing a source of growth factors and other anti-catabolic growth factors and cytokines. Tissue specific microparticles packed together at, or past, their percolation threshold will provide the necessary mechanical environment and to best recapitulate and integrate with native tissue. The packing of microparticles, derived from the ECM of native tissue to a concentration past the percolation point will yield both the necessary biochemical and biomechanical properties necessary for reconstituting a specific tissue.

This invention discloses a silk fibroin-based biomimetic artificial tympanic membrane with a gradient structure and its preparation method, comprising the following steps: encapsulating and dissolving an antibacterial drug in an organic solvent and then adding it dropwise to a silk fibroin solution; casting the film and inducing the formation of a β-sheet structure with methanol to obtain an outer dense layer; electrospinning the silk fibroin solution to obtain oriented silk fibroin fiber felt, and cross-linking it in an ethanol solution to obtain an intermediate fiber layer; mixing the silk fibroin solution with a pore-forming agent and casting it onto the intermediate fiber layer; covering the intermediate fiber layer with the outer dense layer; after pre-freezing and lyophilizing, immersing the membrane in deionized water to dissolve the pore-forming agent to form an inner porous layer; then placing it in a PBS buffer containing growth factors and shaking treatment; and finally drying to obtain the silk fibroin-based biomimetic artificial tympanic membrane with a gradient structure. This invention's three-layer biomimetic artificial tympanic membrane possesses antibacterial and regenerative functions, while also exhibiting excellent mechanical properties, meeting the requirements of a biomimetic tympanic membrane.

Provided herein are polynucleotides comprising a coding sequence for expression of a fibroblast growth factor 21 (FGF21) pathway activating agent. Also provided are vectors, recombinant viral genomes, and recombinant virus compositions comprising said polynucleotides, as well as associated methods.

The application relates to the technical field of medical dressing preparation, and discloses a hemostatic, healing-promoting and antibacterial foam dressing and a preparation method thereof. The method uses sodium alginate and carboxymethyl chitosan as a composite polysaccharide matrix, mixes the two, adds a calcium chloride solution to crosslink a porous gel support, and then carries out freeze-drying to obtain a porous framework; gelatin and polyvinyl alcohol can be further added to enhance the mechanical strength, zeolite particles loaded with silver ions are added to achieve antibacterial performance, epidermal growth factor release microspheres are added to promote healing, and the dressing can be further subjected to heparinization, plasma surface modification, thrombin addition, salt precipitation pore formation and sterilization treatment. The dressing prepared by the method has the functions of synergistic hemostasis, antibiosis and healing promotion, has good biocompatibility and suitable mechanical strength, and has a simple preparation process, and can be used for various wound care.

This invention discloses a fusion protein targeting the urokinase-type plasminogen activator receptor and its application in the field of anti-aging. The fusion protein is composed of a hepatocyte growth factor active domain and a humanized anti-uPAR single-domain antibody linked by a flexible linker peptide, and its specific amino acid sequence is SEQ ID NO:3. This fusion protein can specifically bind to uPAR, which is highly expressed on the surface of senescent cells, with intramolar affinity, achieving targeted delivery of the hepatocyte growth factor active domain. In vitro experiments have demonstrated that this protein can significantly reverse the aging phenotype of human fibroblasts, effectively reduce aging-related β-galactosidase activity, p16INK4a protein expression, and interleukin-6 secretion, and promote cell proliferation. In a rapidly aging mouse model, this protein can systematically improve age-related physiological functional decline. The fusion protein of this invention achieves specific targeting and efficient treatment of senescent cells, providing a new solution for the development of anti-aging drugs.

The present invention is concerned with a protein oligomer comprising (i) at least two NC-1 monomers of collagen 18 or (ii) at least two endostatin domains of collagen 18 or (iii) at least two N-terminal peptides of the collagen 18 endostatin domain, for use in treating, ameliorating or preventing fibrosis or a fibrosis-associated disease, a vascular endothelial growth factor (VEGF)-related disease or a matrix metalloproteinase (MMP)-related disease. The invention further relates to the mentioned protein oligomer for use for detecting and / or diagnosing fibrosis or a fibrosis-associated disease, a vascular endothelial growth factor (VEGF)-related disease or a matrix metalloproteinase (MMP)-related disease.